NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia · Delayed Price · Currency is AUD 0.0660
+0.0010 (1.54%)
Jul 15, 2026, 10:43 AM AEST
NeuroScientific Biopharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Four out of five patients with fistulizing Crohn's disease showed strong clinical response to StemSmart in a Special Access Program, prompting two phase II trials to launch by year-end. The therapy is safe, systemically administered, and targets a major unmet need in Crohn's, with global commercialization and regulatory milestones underway.
Fiscal Year 2025
-
A new stem cell platform was acquired, shifting focus to Crohn's disease and other high-value indications. Early clinical data is strong, with a special access program underway and phase two trials planned. Manufacturing and advisory partnerships de-risk development and support future expansion.